Vaginal Cancer News and Research

RSS

Vaginal cancer (cancer of the vagina) is a rare type of cancer. The most common symptom of vaginal cancer is painless bleeding from the vagina.

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

41st Annual Meeting on Women's Cancer to be hosted in San Francisco, California

The Society of Gynecologic Oncologists (SGO) will host its 41st Annual Meeting on Women's Cancer March 14-17, 2010 at the Moscone West Convention Center in San Francisco, California. This year's meeting will feature more than 434 scientific presentations in addition to lectures, workshops, symposia and postgraduate courses that focus on emerging science, clinical trials and treatment advances for physicians and health care professionals in the field of gynecologic oncology.

11 Feb 2010

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

The U.S. Food and Drug Administration today approved use of the vaccine Gardasil for the prevention of genital warts (condyloma acuminata) due to human papillomavirus (HPV) types 6 and 11 in boys and men, ages 9 through 26.

19 Oct 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Swinging 60s saw a rise in HPV related cancers

Rates for cancers linked to a sexually-transmitted virus have increased in the post World War II baby boomer generation according to new research published in the British Journal of Cancer (Wednesday February 4).

5 Feb 2009

Comprehensive assessment of burden of HPV-associated cancers in the U.S.

Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, MD, PhD and Assistant Professor Edward Peters, DMD, SM, ScD, at LSU Health Sciences Center New Orleans School of Public Health contributed five papers to the largest most comprehensive assessment of the burden of human papillomavirus (HPV)-associated cancers in the United States to date.

11 Nov 2008

FDA approves expanded uses for Gardasil for vaginal and vulvar cancer caused by HPV

The U.S. Food and Drug Administration has announced the approval of the vaccine Gardasil for the prevention of vaginal and vulvar cancer caused by Human Papillomavirus (HPV) types 16 and 18 in girls and women ages 9 to 26.

14 Sep 2008

Advanced Cancer Therapeutics licenses technology to develop HPV vaccine

Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.

23 Jul 2008

Risk of Bisphenol A in plastic products, Q & A's

Bisphenol A, an estrogenlike compound in polycarbonate plastics and epoxy resin, has been popping up in the news a lot lately.

30 Apr 2008

Women who have precancerous lesions removed have increased risk of developing cervical, vaginal cancer for at least 25 years

Women who have precancerous lesions removed from their cervix are at an increased risk of developing cervical or vaginal cancer during the 25 years after the procedure, according to a study published on Friday in BMJ, Reuters reports.

29 Oct 2007

Twice the risk of cervical cancer despite operation

Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.

28 Oct 2007

Women still face cancer risk 25 years after treatment

Women are still at risk of developing invasive cancer of the cervix or vagina 25 years after being treated for pre-cancerous lesions, according to a study published today on bmj.com.

25 Oct 2007

International studies show high efficacy for Gardasil

A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer, strains 16 and 18.

1 Jun 2007

Methoxychlor (MXC), a common insect pesticide may lead to reduced fertility in women

Methoxychlor (MXC), a common insect pesticide used on food crops, may interfere with proper development and function of the reproductive tract, leading to reduced fertility in women, researchers at Yale School of Medicine write in the August issue of Endocrinology.

19 Sep 2005

Methoxychlor (MXC) may interfere with proper development and function of the reproductive tract, leading to reduced fertility in women

The researchers found that MXC, which was manufactured as a safer replacement for the now-banned DDT, alters the estrogen-regulated gene Hoxa10 in the reproductive tract and reduces the ability of the uterus to support embryo implantation. The researchers used mice and then human cell lines to confirm their findings.

7 Sep 2005

Harmful chemicals may reprogram gene response to estrogen

New research shows that exposure to harmful chemicals and drugs during critical developmental periods early in life may actually "reprogram" the way certain genes respond to the female hormone estrogen. This genetic reprogramming may determine whether people with a genetic predisposition for a disease actually develop the disease.

1 Jun 2005